Wells Fargo’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Wells Fargo’s Portfolio GNOM Stock Details GNOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.06K	Hold	24	–	–	﹤0.01%	6327
2025 Q4	$1.11K	Sell	24 -1	-4%	-$44	﹤0.01%	6277
2025 Q3	$958	Sell	25 -13	-34%	-$471	﹤0.01%	6258
2025 Q2	$1.27K	Buy	38 +25	+192%	+$792	﹤0.01%	6282
2025 Q1	$399	Sell	13 -431	-97%	-$16.4K	﹤0.01%	6284
2024 Q4	$17.2K	Buy	+444	New	+$18.7K	﹤0.01%	5801
2024 Q3	–	Hold	0	–	–	–	6867
2024 Q2	–	Hold	0	–	–	–	6721
2024 Q1	–	Hold	0	–	–	–	7449
2023 Q4	–	Hold	0	–	–	–	7541
2023 Q3	–	Hold	0	–	–	–	7547
2023 Q1	–	Hold	0	–	–	–	7520
2022 Q4	–	Hold	0	–	–	–	7351
2022 Q3	–	Hold	0	–	–	–	6898
2022 Q2	–	Hold	0	–	–	–	7049
2022 Q1	–	Sell	-375	Closed	-$23.7K	–	7326
2021 Q4	$30K	Buy	+375	New	+$31.5K	﹤0.01%	6188
2021 Q3	–	Hold	0	–	–	–	7168
2021 Q2	–	Hold	0	–	–	–	7087

Other funds holding GNOM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

OAM

Oppenheimer Asset Management New York $8.76B AUM 23.12% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

USCWA

U.S. Capital Wealth Advisors Austin, Texas $3.98B AUM 22.36% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

Armis Advisers Atlanta, Georgia $1.09B AUM 22.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

CFD

Creative Financial Designs Kokomo, Indiana $1.65B AUM 15.6% 1-Year Est. Return

Wells Fargo's GNOM Position: Q1 2026 in Review

Wells Fargo held its Global X Genomics & Biotechnology ETF (GNOM) position steady in Q1 2026 at 24 shares worth $1.06K. The position accounts for ﹤0.01% of the portfolio, ranked #6327.

Wells Fargo first reported a position in GNOM in Q4 2021 and has held it in 7 quarters since. The position peaked at $30K in Q4 2021. 40 funds tracked by Wall St. Rank hold GNOM as of Q1 2026.

Wells Fargo held 24 shares of Global X Genomics & Biotechnology ETF worth $1.06K as of Q1 2026.
Wells Fargo left its Global X Genomics & Biotechnology ETF share count unchanged in Q1 2026.
Global X Genomics & Biotechnology ETF made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #6327 holding.
Wells Fargo first reported a position in Global X Genomics & Biotechnology ETF in Q4 2021 and has held it in 7 quarters since.
Wells Fargo's Global X Genomics & Biotechnology ETF position peaked at $30K in Q4 2021.
40 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.